The ARKG ETF is an exciting investment vehicle that focuses on companies at the forefront of the genomics industry. Its largest holding, CRISPR (ticker: CRSP), is a Swiss-based company that is pioneering developments in gene-editing technology, with the potential for commercialization on the horizon.
The implications of gene editing are profound, with scientists suggesting it could transform fields ranging from medicine to agriculture. There's even the possibility of editing the genetic makeup of entire species, which is as daunting as it is fascinating. The scenario where affluent individuals use this technology to combat aging or engineer 'designer babies' isn't far-fetched. It echoes the way people invest in bespoke traits for their pets.
On a personal note, I've taken a significant position in both the broader ETF and CRISPR's stock itself. I entered ARKG at $103, and it's currently at $93, while CRISPR, bought at $128, has climbed to $134. I’m in this for the long haul, hopeful that by the time I reach 50, these investments will have soared, potentially funding my own leap into immortality through gene preservation. Time will tell!
